Novel mitogen-activated protein kinase kinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 209-220

  Chapman, Mark S ^a   Miner, Jeffrey N ^b  

^a BIOGEN   (United States)

^b Ardea Biosciences   (United States)

Author keywords

anabolic androgenic steroids; chronic illnesses; testosterone; weight loss

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ADALIMUMAB; ANTINEOPLASTIC AGENT; ARRY 438162; AS 703062; AZD 8330; BAY 869766; CAPECITABINE; CH 4987655; CISPLATIN; E 6201; ETANERCEPT; GDC 0973; GEMCITABINE; GSK 1120212; IMATINIB; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PEMETREXED; RDEA 119; RDEA 436; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RO 4987655; RO 5126766; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 518;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BINDING SITE; BLURRED VISION; BREAST CANCER; CANCER FATIGUE; COLON CANCER; COLORECTAL CANCER; COMPETITIVE INHIBITION; CONFUSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HALLUCINATION; HEART LEFT VENTRICLE FAILURE; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PSORIASIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEADY STATE; SYNCOPE; THYROID CANCER; TUMOR XENOGRAFT; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENES, RAS; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 79951928689     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.548803     Document Type: Review

References (60)

1. Weinberg RA. Oncogenes and tumor suppressor genes. CA Cancer J Clin 1994;44(3):160-70. (Pubitemid 24190197)
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-49.
3. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283(2):125-34.
4. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682-9. (Pubitemid 19213607)
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54. (Pubitemid 34716871)
6. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18(3):813-22. (Pubitemid 29080340)
7. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997-7000. (Pubitemid 35424092)
8. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28(7):742-62. (Pubitemid 350294294)
9. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22(4):708-22. (Pubitemid 351565619)
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11. (Pubitemid 39209661)
11. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109(7):863-7. (Pubitemid 34275106)
12. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68(9):3077-80, discussion 80.
13. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68(14):5524-8.
14. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16.
15. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26(22):3291-310. (Pubitemid 46763022)
16. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4(12):937-47. (Pubitemid 39626217)
17. Sharma A, Tran MA, Liang S, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66(16):8200-9. (Pubitemid 44299188)
18. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63(18):5669-73. (Pubitemid 37187459)
19. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11(12):1192-7.
20. Catalanotti F, Reyes G, Jesenberger V, et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 2009;16(3):294-303.
21. Scholl FA, Dumesic PA, Barragan DI, et al. Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res 2009;69(9):3772-8.
22. Skarpen E, Flinder LI, Rosseland CM, et al. MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J 2008;22(2):466-76. (Pubitemid 351225583)
23. Ussar S, Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 2004;279(42):43861-9. (Pubitemid 39390693)
24. Sebolt-Leopold JS. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004;10(16):1907-14. (Pubitemid 38647576)
25. Haystead TA, Dent P, Wu J, et al. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 1992;306(1):17-22.
26. Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7(14):1364-78. (Pubitemid 47471235)
27. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62. (Pubitemid 43128863)
28. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007;6(23):2902-5.
29. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4(1):28-35.
30. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47(4):409-14.
31. Weissmann G. The pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2006;64(1-2):12-5. (Pubitemid 44625527)
32. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273(29):18623-32. (Pubitemid 28334795)
33. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5(7):810-16. (Pubitemid 29318616)
34. Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008;18(24):6501-4.
35. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23(23):5281-93. (Pubitemid 46206982)
36. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22(22):4456-62. (Pubitemid 41185111)
37. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(8):2450-7.
38. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13(5):1576-83. (Pubitemid 46450450)
39. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46.
40. Hersey P, Bastholt L, Chiarion-Sileni V, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009;20(Suppl 6):vi35-40.
41. Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;69(17):6839-47.
42. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007;104(50):19936-41.
43. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007;7(5):617-26. (Pubitemid 46805560)
44. Goto M, Chow J, Muramoto K, et al. E6201 [(3S,4R,5Z,8S,9S,11E)-14- (ethylamino)-8, 9,16-trihydroxy-3,4- dimethyl-3,4,9,19-tetrahydro-1H-2- benzoxacyclotetradec ine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 2009;331(2):485-95.
45. Matsumoto K, Nagahara T, Okano J, Murawaki Y. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 2008;20(4):863-72.
46. Holcomb B, Yip-Schneider MT, Matos JM, et al. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg 2008;12(2):288-96.
47. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14(1):230-9. (Pubitemid 351378000)
48. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6(8):2209-19. (Pubitemid 47294749)
49. Katayama K, Yoshioka S, Tsukahara S, et al. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007;6(7):2092-102. (Pubitemid 47052500)
50. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19.
51. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431- 5.
52. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):902-3.
53. Corcoran RB, Dias-Santagata D, Bergethon K, et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3(149):ra84.
54. Yip-Schneider MT, Klein PJ, Wentz SC, et al. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009;329(3):1063-70.
55. Legrier ME, Yang CP, Yan HG, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67(23):11300-8.
56. Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer 2010;10:515.
57. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15(14):4649-64.
58. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69(2):565-72.
59. O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3¢ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16(14):3670-83.
60. Turke AB, Engelman JA. PIKing the right patient. Clin Cancer Res 2010;16(14):3523-5